APOBEC2 (aa12 _ 26) Antibody
- Known as:
- APOBEC2 (aa12 _ 26) Antibody
- Catalog number:
- AF1078a
- Product Quantity:
- 0.1mg
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- APOBEC2 (aa12 _ 26) Antibody
Related genes to: APOBEC2 (aa12 _ 26) Antibody
- Gene:
- APOBEC2 NIH gene
- Name:
- apolipoprotein B mRNA editing enzyme catalytic subunit 2
- Previous symbol:
- -
- Synonyms:
- ARCD1, ARP1
- Chromosome:
- 6p21.1
- Locus Type:
- gene with protein product
- Date approved:
- 1999-08-12
- Date modifiied:
- 2016-10-05
Related products to: APOBEC2 (aa12 _ 26) Antibody
Related articles to: APOBEC2 (aa12 _ 26) Antibody
- Genome-wide association studies (GWASs) have identified single-nucleotide polymorphisms (SNPs) at the 6p21.1 locus associated with gastric cancer (GC) risk. However, the underlying biological mechanisms remain poorly understood. - Source: PubMed
Publication date: 2026/05/12
Zheng ZhonghuaLi QianGu YuanliangGao XinxiangWang XinyaZhang YanAn FangmeiZhan QiangYin ShuangshuangGao YunPeng RuiLiu LiZhang ErbaoZhu MengChen XiaofengLi GangXu HaoJin GuangfuYan Caiwang - To study a non-redundant role of Tcf12 in retinal health. - Source: PubMed
Yu TianUlker-Yilmazer GizemKirman Dogan CanTurpin Emily RYuksel SeherHe Yu-GuangLudwig SaraKumar AshwaniXing ChaoEvers BretMoresco Eva Marie YBeutler Bruce AAredo BogaleUfret-Vincenty Rafael L - AllergoOncology has emerged as an interdisciplinary field exploring the interaction between allergic diseases and cancer; however, the lack of stable in vivo models has limited mechanistic investigations. This study aimed to establish an experimental animal model to explore the impact of systemic allergic responses on tumor progression and to provide preliminary insights into the regulatory role of allergy in cancer development. - Source: PubMed
Publication date: 2026/04/08
Fan XiaoyuGuo ShushuZhang WenchaoXu ZeaoSun SimanLi YanHe JiumingJin Hongtao - Rhabdomyosarcoma (RMS) is an aggressive cancer thought to arise from impaired myogenesis. This can be substantially overcome by increasing the levels of pannexin 1 (PANX1), a critical component of the myogenic program, but the mechanism involved is unknown. Using RNA-seq, we have previously found that overexpression of PANX1 dramatically reshapes the transcriptomic landscape of RMS including downregulation of a myogenic modulator, APOBEC2 (apolipoprotein B mRNA editing enzyme catalytic subunit 2). Following this clue, we investigated the role of APOBEC2 in the PANX1-mediated suppression of RMS malignancy. Here we show that, using a panel of patient-derived RMS cell lines and tumor specimens, APOBEC2 is expressed in RMS, but that its levels are lower than those in both differentiating myoblasts and skeletal muscle. In most RMS cell lines examined, APOBEC2 accumulates during proliferation and sustains their stem-like characteristics, as evidenced by its ability to promote the growth of spheroids upon increased expression. Yet, ectopic PANX1 expression led to a marked downregulation of APOBEC2 across a large proportion of RMS cell lines assessed. Strikingly, these were the same cells in which PANX1 triggers multinucleation. We further reveal that, like healthy myoblasts progressing through myogenesis, the multinucleation observed here in RMS cells results from cell fusion. Importantly, in RMS cells engineered to overexpress APOBEC2, PANX1 no longer enhances cell fusion, but its other anti-tumorigenic properties are still preserved. Collectively, our data indicate that PANX1 promotes RMS cell fusion by downregulating APOBEC2 expression, driving these tumor cells further into the myogenic program. - Source: PubMed
Publication date: 2025/11/18
Welten AlexandraBera AmitLanglois StéphanieXiang XiaoGupta KeshavFreeman EmilyCowan Kyle N - The APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) family plays a vital mutagenic role in diverse human malignancies. Nevertheless, the biological characteristics of APOBEC family members and their clinical significance in cancer have not been comprehensively explored. Our primary objective was to characterize the distribution and clinical relevance of APOBEC family members and their mutations across multiple cancer types, with a particular focus on thyroid carcinoma (THCA). - Source: PubMed
Publication date: 2025/07/26
Luo WeiLiu FengLi MengyuYu JialongLiu ZiyunCheng XuanHuang YueLiu YuTao MeiWang YuqiZou YipingShang XiaobinYang ChaoRuan XianhuiQin YanchaoZheng Xiangqian